Lee D. Cranmer, MD, PhD, FACP

Director of Sarcoma Medical Oncology
Fred Hutch
Associate Professor
University of Washington School of Medicine
Associate Professor, Clinical Research Division
Fred Hutch
Specialty:
Medical Oncology
“You are more than a patient: You are a critical partner in our research efforts. If we hope to improve cancer care, it will only be by working together.”
— Dr. Cranmer
What made you want to practice oncology?

Several of the mentors and role models in my early life were physicians, and I always knew I wanted to work in a field where my efforts would directly improve the world. While I was a medical resident at the Mayo Clinic, I worked in the cancer ward and quickly realized there were unmet needs for people with cancer, which made me want to continue working with them to see how I could help. I believe that immunotherapy will provide a means to treat the disease more effectively and even prevent it in some cases. I expect to make this the focus of the rest of my career.

Immunotherapy A type of therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer, infection and other diseases. A therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer, infection and other diseases. Some immunotherapies only target certain cells of the immune system. Others affect the immune system in a general way. Types of immunotherapy include cytokines, vaccines, bacillus Calmette-Guerin (BCG) and some monoclonal antibodies.
Lee_D_Cranmer_Secondary.jpg
How do you partner with your patients?

I believe in a team-based approach to cancer care, with you at the center of the team. You are also a vital partner in our scientific work, as well as the direct beneficiary of our past and current laboratory research and clinical trials. Although most discoveries lead to only incremental improvements, I’ve been honored to participate in research that has been groundbreaking in its impact on the people we care for.

Provider background

Specialty: Medical Oncology

Area of clinical practice

Sarcomas

Sarcomas

As the director of Sarcoma Medical Oncology, my expertise is in the clinical management of sarcomas, a rare kind of cancer that grows in connective tissue — cells that connect or support other kinds of tissue in your body. I am focused on supporting and expanding sarcoma research collaborations at Fred Hutchinson Cancer Research Center and UW Medicine, including the development of local clinical trials, involvement in national clinical trials, the teaching and mentoring of hematology-oncology fellows and community-outreach activities.

Skin cancers

I treat patients with melanoma and non-melanoma skin cancers. I’ve been directly involved in the design or execution of over 70 institutional, industry and national cooperative group-sponsored therapeutic clinical trials for melanoma and sarcoma patients, in addition to phase 1 solid tumor protocols. These have included trials of molecularly targeted therapies and immune-boosting therapies, such as immune checkpoint inhibitors.

Melanoma Cancer that begins in the melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but it can also begin in other pigmented tissues, such as the eye or the intestines. Targeted therapy A type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells while causing less harm to normal cells. A type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells while causing less harm to normal cells. Some targeted therapies block the action of certain enzymes, proteins or other molecules involved in the growth and spread of cancer cells. Other types of targeted therapies help the immune system kill cancer cells, or they deliver toxic substances directly to cancer cells and kill them. Targeted therapy may have fewer side effects than other types of cancer treatment. Most targeted therapies are either small molecule drugs or monoclonal antibodies.

Diseases treated

Education, experience and certifications
Undergraduate Degree
Harvard University
Medical Degree
University of California, San Diego
Residency
Mayo School of Graduate Medical Education, Internal Medicine
Fellowship
University of Arizona College of Medicine, Medical Oncology
Board Certification
Medical Oncology, 2004, 2014; Internal Medicine, 2001, 2011, American Board of Internal Medicine
Other
PhD, University of California, San Diego; MSc, Liverpool School of Tropical Medicine; Master, University of Liverpool; MPH, University of Arizona; Teaching Appointment, University of Arizona
Languages
English

Stories

West Coast Sarcoma Conference 2022
West Coast Sarcoma Conference 2022

A two-day conference on the treatment of sarcoma presented by Seattle Cancer Care Alliance, Fred Hutch and University of Washington School of Medicine.

Research

Clinical trials

We make promising new treatments available to you through studies called clinical trials led by Fred Hutch doctors. Many of these trials at Fred Hutch have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.

Study ID:
NCT04833582
A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma
Complete title
A Phase 1/2 Dose Escalation and Dose Expansion Study of ZN-c3 in Combination with Gemcitabine in Adult and Pediatric Subjects with Relapsed or Refractory Osteosarcoma
Study ID:
NCT03600649
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
Complete title
Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP-2577) with and without Topotecan and Cyclophosphamide in Patients with Relapsed or Refractory Ewing Sarcoma and Select Sarcomas
Study ID:
NCT04480502
ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma (ENVASARC)
Complete title
ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB, AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB, IN PATIENTS WITH ADVANCED OR METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA OR MYXOFIBROSARCOMA WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY.

Publications

Many of our Fred Hutch doctors conduct ongoing research to improve standards of patient care. Their work is evaluated by other doctors and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this Fred Hutch provider has written.

Your care team

At Fred Hutch, you receive care from a team of providers with extensive experience in your disease. Your team includes doctors, a patient care coordinator, a registered nurse, an advanced practice provider and others, based on your needs. You also have access to experts like nutritionists, social workers, acupuncturists, psychiatrists and more who specialize in supporting people with cancer or blood disorders.
Registered nurse (RN)
Registered nurse (RN)
Your nurse manages your care alongside your doctor and assists with care procedures and treatments.
Patient care coordinator
Patient care coordinator
Your patient care coordinator works closely with you and your doctor and serves as your scheduler.

Insurance

Fred Hutch accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.